Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano, Italy.
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Respirology. 2018 Dec;23(12):1098-1113. doi: 10.1111/resp.13393. Epub 2018 Sep 6.
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) is the deadliest infectious disease and the associated global threat has worsened with the emergence of drug resistance, in particular multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Although the World Health Organization (WHO) End-TB Strategy advocates for universal access to antimicrobial susceptibility testing, this is not widely available and/or it is still underused. The majority of drug resistance in clinical MTB strains is attributed to chromosomal mutations. Resistance-related mutations could also exert certain fitness cost to the drug-resistant MTB strains and growth fitness could be restored by the presence of compensatory mutations. Understanding these underlying mechanisms could provide an important insight into TB pathogenesis and predict the future trend of MDR-TB global pandemic. This review covers the mechanisms of resistance in MTB and provides a comprehensive overview of current phenotypic and molecular approaches for drug susceptibility testing, with particular attention to the methods endorsed and recommended by the WHO.
结核病(TB)是由结核分枝杆菌(MTB)引起的,是最致命的传染病,随着耐药性的出现,包括耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)在内的全球威胁日益加剧。尽管世界卫生组织(WHO)的终结结核病战略提倡普及抗微生物药物敏感性测试,但这在全球范围内还没有得到广泛应用和/或仍未得到充分利用。临床 MTB 菌株中的大多数耐药性归因于染色体突变。耐药相关突变也可能对耐药 MTB 菌株产生一定的适应性代价,而代偿性突变的存在可以恢复其生长适应性。了解这些潜在的机制可以为结核病的发病机制提供重要的见解,并预测 MDR-TB 全球大流行的未来趋势。本综述涵盖了 MTB 耐药的机制,并全面概述了目前用于药物敏感性测试的表型和分子方法,特别关注了 WHO 认可和推荐的方法。